But this is a typical Novanta solution that we employ also in robotics or broader material processing or I would argue DNA sequencing, right? So, we enable productivity improvements for the end user and customers. So for example, in DNA sequencing is really driving the cost per test and genome down as a result of our core engine into those applications, right? So it’s a very similar trend and approach across these applications and customers, which is why we’re intrinsic and detailed and very differentiated part of their supply chain. So when we give all these examples, the themes typically or the solutions typically head on many of these themes in parallel, right, which is ultimately why we’re extracting value from it. Our customers are extracting value from it and the end users are extracting value from it.
Robert Buckley: The only thing I would add there is that we have used an acquisition strategy as well to acquire in technologies that allow us to redefine the competitive landscape. And so, as a consequence, we don’t offer solutions that a competitor can match. We offer solutions that we’ve uniquely combined through a number of different acquisitions that our competitors haven’t even thought of or looked at, that allows us to really offer a solution to a customer from their lens, from their eyes. And so, I think that’s ultimately been the big differentiation that we’ve had, is that we don’t offer solutions based on the widget that we offer. We offer solutions based on what the customer is looking to solve.
Lee Jagoda: Got it. And just, I guess one more and I’ll hop back in queue. As it relates to M&A. You kind of teased we’ll see something before year end. Can you give us any framework around you know size, mix of business that you’re looking at? Anything to kind of lead us down a path in terms of what you’re looking to acquire at this point?
Matthijs Glastra: Yes, I think what we’ve said is that, listen, we’re leaning into these macro trends that we’ve discussed, right? The overall growth framework is we get more content and solve more unique ways of solving our problem. Like what Robert suggested, right in his previous remarks into these high-growth applications. And so, of course, you know, we have had a tendency over the years to be more geared towards medical end markets as well as growing advanced industrial end markets, robotics and automation. So, you can expect us to continue to lean into those trends and further enhance, I think, our exposure into those end markets. As a reminder, 60% of our business is now or close to is in medical end markets. That’s up from, I would say, mid-single digits 10 years ago. That’s both organically as well as through acquisition, and we like that general exposure. So, let me leave it at that.
Lee Jagoda: Okay, thanks very much.
Matthijs Glastra: Thanks, Lee.
Operator: The next question comes from Brian Drab of William Blair. Please go ahead.
Brian Drab: Hi, thanks for taking the questions.
Matthijs Glastra: Hey. Good morning.
Brian Drab: Good morning. Robert, you said and I just kind of missed all the context, but you said acceleration in 2024 potentially. Can you just restate that and elaborate on the drivers that you’re talking about at the moment?
Robert Buckley: Yes, so I would say regardless of how the market performs, our second half of the year of 2024 will be accelerating on the back of new product launches. So, we have a number of customer launches that we’ve talked about in the past. We have launches now associated with our second generation smoke evacuation platform. There are a handful of customers launching products in the back half of 2024 around that. We have customers looking to launch and ramp as Matthijs just spoke about our next-generation lithography solutions. And we have a couple of new design wins around integrated operating room-based technologies and some precision medicine-based technologies. And so, a lot of these things were meant to be spread out across 2024.
